Davide Serrano

Medicine & Life Sciences

1. Tamoxifen 100%
2. Breast Neoplasms 90%
3. Fenretinide 49%
4. Neoplasms 35%
5. Colorectal Neoplasms 31%
6. Chemoprevention 31%
7. Placebos 30%
8. Breast 28%
9. Calcitriol Receptors 22%
10. Cytochrome P-450 CYP2D6 22%
11. Carcinoma, Intraductal, Noninfiltrating 22%
12. Biomarkers 20%
13. Insulin-Like Growth Factor I 20%
14. APC Genes 20%
15. Breast Diseases 18%
16. Adenomatous Polyposis Coli 17%
17. Estrogen Receptors 16%
18. Metformin 15%
19. Breast Carcinoma In Situ 15%
20. Insulin-Like Growth Factor Binding Protein 3 15%
21. Confidence Intervals 15%
22. Common Variable Immunodeficiency 15%
23. Meta-Analysis 15%
24. exemestane 15%
25. Metagenomics 14%
26. Estradiol 14%
27. Genotype 14%
28. Hereditary Nonpolyposis Colorectal Neoplasms 14%
29. Vitamin D 13%
30. Breast Density 13%
31. Mutation 12%
32. Retinoids 12%
33. T-Lymphocytes 12%
34. Choline 11%
35. Genes 11%
36. Microbiota 11%
37. Recurrence 11%
38. Sex Hormone-Binding Globulin 10%
39. Stomach Neoplasms 9%
40. Budesonide 9%
41. Hormone Replacement Therapy 8%
42. Datasets 8%
43. 4-hydroxy-N-desmethyltamoxifen 8%
44. Cadherins 8%
45. Estrogen Replacement Therapy 8%
46. Metagenome 8%
47. Therapeutics 8%
48. Hormones 7%
49. Precision Medicine 7%
50. Anastrozole 7%